Latest Investor Confidence News

Prestal Holdings reported a sharp 25% revenue decline and a staggering 133% increase in net loss for FY2025, yet still declared a special dividend and capital return.

Enterprise Metals Limited has addressed recent sharp price and volume movements in its shares, attributing the activity to upcoming drilling programs and positive market sentiment in rare earth elements and critical minerals.

Aspermont Limited invites existing shareholders to participate in a $1.25 million Share Purchase Plan at a premium price, supporting its pivot to data-driven intelligence services and a strategic Rio Tinto partnership.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

Prescient Therapeutics has completed a $3 million share placement, bolstering its clinical development programs for innovative cancer treatments including PTX-100 and novel cell therapies.

Phoslock Environmental Technologies reports a sharp revenue increase driven by Brazil and international markets, yet continues to face significant losses and ongoing legal challenges.

Blue Energy Limited has successfully raised $3.2 million through a two-tranche placement, complemented by a proposed $250,000 share purchase plan, to fund drilling and pipeline development in Queensland’s North Bowen Basin.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

Finexia Financial Group's shares have been suspended from trading pending a significant announcement related to media speculation and a potential material acquisition.

Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.

Harvey Norman Holdings Limited reported robust FY25 results with strong sales growth, a significant profit increase, and a major boost from property revaluations. The company’s integrated retail, franchise, and property model continues to underpin its expansion and resilience.

Harvey Norman Holdings reported a robust 39% jump in profit before tax for FY25, driven by strong franchise sales, a booming property portfolio, and strategic international expansion.